389
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)

ORCID Icon, , , , , ORCID Icon, ORCID Icon, , , , , ORCID Icon, ORCID Icon, ORCID Icon, , , ORCID Icon, ORCID Icon, , ORCID Icon & ORCID Icon show all
Pages 3232-3236 | Received 09 May 2022, Accepted 17 Aug 2022, Published online: 10 Sep 2022
 

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Additional information

Funding

BJB receives funding from the National Institute of Health K12 grant # 5K12CA001727-27.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.